and Aventis signed an agreement to end their development and commercialization pact for the cancer drug Genasense.
In November, Aventis, part of
, provided Genta with a notice of termination of the arrangement.
The agreement ends the financial obligations of each company, and the line of credit established by Aventis to Genta will be retired. Aventis will also return its current inventory of Genasense to Genta.
In addition, Genta will assume responsibility for the clinical trial of Genasense in combination with docetaxel in prostate cancer patients, which is under way in Europe.
Genasense inhibits the production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced programmed cell death. Genta is evaluating the product's potential to treat various forms of cancer.